查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1855638

PD-1 和 PD-L1 抑制剂市场按产品类型、适应症、最终用户、分销管道、给药途径和公司划分 - 全球预测 2025-2032 年

PD-1 & PD-L1 Inhibitors Market by Product Type, Indication, End User, Distribution Channel, Route Of Administration, Company - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，PD-1 和 PD-L1 抑制剂市场将成长至 2,080.6 亿美元，复合年增长率为 21.22%。

主要市场统计数据
基准年 2024 446.1亿美元
预计年份：2025年 539.1亿美元
预测年份：2032年 2080.6亿美元
复合年增长率 (%) 21.22%

一份关于PD-1和PD-L1抑制剂的策略性入门指南，阐述了其临床成熟度、竞争优势以及对肿瘤学相关人员的系统性影响。

免疫查核点抑制剂领域已从概念验证发展成为现代肿瘤学的基石，这主要得益于标靶PD-1和PD-L1的疗法。这些药物使以往全身性治疗选择有限的患者群体获得了持久的疗效，改变了多种肿瘤的治疗模式。因此，生物製药、肿瘤临床实践和政策相关人员正在调整其产品组合、临床路径和报销策略，以适应免疫调节在组合方案和长期疾病控制中发挥核心作用的时代。

科学组合策略、监管灵活性和商业性创新如何融合，从而重新定义免疫查核点疗法的治疗轨迹

PD-1和PD-L1抑制剂的治疗格局正受到科学、监管和商业性因素的共同影响而转变。从机制上看，该领域正从单药治疗转向将查核点抑制剂与标靶治疗、细胞毒性药物、抗血管生成药物以及新型免疫调节剂进行合理联合治疗，以扩大患者获益并克服抗药性。这种方向的转变迫使临床负责人采用适应性强的方案和富含生物标记的队列，以加速讯号检测并优化资源配置。

近期美国关税政策变化对生技药品供应链、生产策略、临床试验连续性和商业合约动态的广泛影响

美国关税调整和贸易政策的演变将对生物肿瘤产品的临床供应链、生产决策和商业策略产生连锁反应。进口组件、成品生技药品或专用耗材关税的提高可能会促使製造商重新评估筹资策略，并透过调整某些生产流程的资源配置或深化与国内契约製造製造商的合作关係来减轻影响。此类变化将影响前置作业时间、资金配置以及灌装和无菌生技药品生产长期产能投资的优先顺序。

从产品类别、肿瘤适应症、医疗环境、分销管道、给药途径和企业策略等多个维度进行细緻的市场观点，以挖掘差异化的商业机会。

对市场细分进行细緻分析，可以发现临床效用和商业策略会因产品类型、适应症、最终用户、分销管道、给药途径和公司所有权的不同而有所差异。在产品类型内部，PD-1抑制剂和PD-L1抑制剂之间的差异在临床和商业性仍然十分显着。以cemipilimab、 Nivolumab和Pembrolizumab等药物为代表的PD-1抑制剂，通常在多种肿瘤类型的单药治疗中具有持久疗效，而以Atezolizumab、 Avelumab和Durvalumab等药物为代表的PD-L1抑製剂则在特定适应症和联合治疗领域占据战略地位。这些治疗模式层面的差异体现在研究设计、安全性管理和标靶产品特性等。

主要地区不同的监管环境、支付方期望和医疗服务体系如何驱动生技药品的差异化准入策略和证据优先排序

美洲、欧洲、中东和非洲以及亚太地区的区域动态影响着药物的可近性、临床应用和战略重点，每个地区都呈现出不同的法律规范、报销文化和医疗服务模式。在美洲，先进的临床试验基础设施和集中化的报销机制促进了新适应症的早期应用和快速整合，而疗效和成本效益指标则是相关人员谈判的重点。欧洲、中东和非洲则呈现出由众多国家监管机构和支付系统组成的复杂格局，这些机构和系统强调卫生技术评估和预算影响分析，要求製造商开发针对特定地区的证据包装和患者准入计划。

竞争对手层面的分析重点在于产品组合优化、组合策略、配方创新和经营能力，以支持在免疫肿瘤学领域的长期领先地位。

主要企业正在优化其产品组合，透过将临床差异化与规模扩张相结合，以保持长期领先地位。阿斯特捷利康专注于策略併购和肿瘤学合作，以强化其适应症和互补资产，并利用其研发网络推出新型联合检测。百时美施贵宝则保持其广泛的免疫肿瘤业务布局，专注于透过联合检测和真实世界证据生成进行生命週期管理，以保持其在各个治疗领域的临床相关性。同时，罗氏正利用其诊断能力和深厚的肿瘤学专业知识，将伴随检测与治疗方案的部署相结合。

製造商和相关人员的策略和营运重点在于提高生技药品的可及性、推动临床差异化以及增强供应和商业性韧性。

行业领导者应协调商业性、临床和营运等多方面资源，以最大限度地提高患者用药可及性，并在不断发展的查核点抑制剂市场中保持竞争优势。在策略层面，他们优先发展能够产生生物标记驱动证据并证明组合方案具有迭加获益的研发管道，以抢占具有临床意义的细分市场。同时，他们正加速投资于製剂创新，特别是皮下给药和固定剂量复方製剂，以降低给药复杂性，拓展门诊治疗模式，同时确保安全性和药物动力学等效性。

采用透明的多方法研究途径，结合同侪审查文献、监管文件、专家访谈和资料三角验证，以确保临床和商业性有效性。

支持这份执行报告的研究采用了一种多方法整合策略，旨在对高品质证据和专家见解进行三角验证。二手文献和同行评审的临床研究为作用机制解读、安全性分析和临床疗效比较提供了科学依据，而监管文件和已发布的製剂资讯则提供了关于核准适应症和给药策略的有效细节。主要研究包括对临床研究人员、医院药剂师、支付方和行业高管进行结构化访谈，以了解未来在推广应用障碍、报销动态和营运限制方面的看法。

整合临床、商业性和营运方面的必要因素，以确定如何将查核点抑制剂的科学进步转化为可持续、可近的癌症治疗。

PD-1 和 PD-L1 抑制剂目前的进展轨迹标誌着该领域正处于战略转折点。科学进步和监管灵活性正在拓展治疗的可能性，而商业和营运压力正在重塑治疗的交付方式。在这种环境下取得成功需要双管齐下：一方面，透过生物标誌物主导的研发和合理的联合用药实现临床差异化；另一方面，在生产、分销和医保支付方参与方面务实地执行。相关人员，将更有能力在应对经济和政策逆风的同时，为病患带来持续的益处。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 新型双特异性抗体标靶PD-1和其他免疫查核点，以克服抗药性机制
  • PD-1/PD-L1抑制剂在早期癌症治疗和辅助性治疗的广泛应用正在改善患者的存活预后。
  • 预测性生物标记和伴随诊断技术的进步将优化PD-1/PD-L1疗法的患者选择
  • PD-1/PD-L1抑制剂、新型标靶治疗和化疗组合方案固体癌的疗效已提高
  • 开发下一代PD-1/PD-L1抑制剂，其特点是安全性更高，临床试验中免疫相关不利事件更少
  • 透过扩大PD-1/PD-L1抑制剂在罕见癌症和非自体免疫疾病的适应症，增加患者获得治疗的机会。
  • 整合真实世界证据与卫生经济学分析，为全球市场PD-1/PD-L1抑制剂的报销决策提供支持

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. PD-1 和 PD-L1 抑制剂市场（依产品类型划分）

  • PD-1
    • 塞米匹利单抗
    • Nivolumab
    • Pembrolizumab
  • PD-L1抑制剂
    • Atezolizumab
    • Avelumab
    • Durvalumab

9. 依适应症分類的PD-1和PD-L1抑制剂市场

  • 膀胱癌
  • 头颈癌
  • 肺癌
  • 黑色素瘤
  • 肾臟细胞癌

10. 按最终用户分類的PD-1和PD-L1抑制剂市场

  • 医院
  • 研究所
  • 专科诊所

11. PD-1 和 PD-L1 抑制剂市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

12. 依给药途径分類的PD-1和PD-L1抑制剂市场

  • 静脉注射
  • 皮下注射

13. 各公司PD-1及PD-L1抑制剂市场

  • AstraZeneca
  • Bristol-Myers Squibb
  • Merck
  • Roche

14. 各地区PD-1及PD-L1抑制剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. PD-1 和 PD-L1 抑制剂市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国PD-1及PD-L1抑制剂市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca PLC
    • Merck KGaA
    • Pfizer Inc.
    • BeiGene, Ltd.
    • Innovent Biologics, Inc.
    • CStone Pharmaceuticals
    • Shanghai Junshi Biosciences Co., Ltd.
Product Code: MRR-4659C8713636

The PD-1 & PD-L1 Inhibitors Market is projected to grow by USD 208.06 billion at a CAGR of 21.22% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 44.61 billion
Estimated Year [2025] USD 53.91 billion
Forecast Year [2032] USD 208.06 billion
CAGR (%) 21.22%

A strategic primer on PD-1 and PD-L1 inhibitors that frames clinical maturation, competitive differentiation, and the systemic implications for oncology stakeholders

The field of immune checkpoint blockade has matured from proof-of-concept to a foundational pillar of modern oncology, driven primarily by therapies that target PD-1 and PD-L1. These agents have shifted paradigms in multiple tumor types by enabling durable responses in patient populations that previously had limited systemic options. As a result, stakeholders across biopharma, oncology practice, and policy are recalibrating portfolios, clinical pathways, and reimbursement approaches to reflect an era where immunomodulation is often central to combination regimens and long-term disease control.

Recent clinical and translational advances have expanded indications and refined patient selection strategies, elevating the importance of biomarkers, trial design, and real-world evidence to guide appropriate use. Simultaneously, competition among established biologic developers and newer entrants has accelerated innovation in formulation, dosing, and combination approaches. Investors and commercial leaders must parse differentiators such as novel administration routes, safety profiles that impact line of therapy, and strategic collaborations that extend lifecycle value. Consequently, this introduction frames the broader clinical and commercial context that underpins subsequent analysis, emphasizing the interplay between scientific progress and practical adoption in health systems.

How scientific combination strategies, regulatory flexibility, and commercial innovation are converging to redefine therapeutic trajectories for immune checkpoint therapies

The therapeutic landscape for PD-1 and PD-L1 inhibitors is undergoing transformative shifts driven by scientific, regulatory, and commercial forces that are converging to reshape standards of care. Mechanistically, the field is moving beyond monotherapy into rational combinations that pair checkpoint inhibitors with targeted agents, cytotoxic regimens, anti-angiogenics, and novel immunomodulators to broaden patient benefit and overcome resistance. These directional changes are prompting clinical trialists to adopt adaptive protocols and biomarker-enriched cohorts to accelerate signal detection and optimize resource allocation.

On the regulatory front, greater willingness to grant accelerated approvals in biomarker-defined populations has incentivized developers to pursue clear translational hypotheses and robust post-marketing evidence plans. Payers, in turn, are evolving reimbursement frameworks to reward value, including outcomes-based and indication-specific arrangements that recognize long-term benefits and manage upfront costs. Commercially, manufacturers are investing in differentiated formulations, such as subcutaneous preparations and fixed-dose regimens, to improve administration economics and patient convenience. Collectively, these shifts are driving consolidation in strategic partnerships, targeted M&A activity focused on complementary modalities, and increased emphasis on supply chain resilience to support broader global access.

The broad repercussions of recent United States tariff shifts on biologics supply chains, manufacturing strategies, clinical trial continuity, and commercial contracting dynamics

Tariff adjustments and trade policy developments in the United States create ripple effects across the clinical supply chain, manufacturing decisions, and commercial strategies for biologic oncology products. When duties increase on imported components, finished biologics, or specialized consumables, manufacturers reassess sourcing strategies, potentially reshoring certain manufacturing steps or deepening relationships with domestic contract manufacturers to mitigate exposure. These shifts have implications for lead times, capital allocation, and the prioritization of long-term capacity investments in fill-finish and sterile biologics manufacturing.

In the commercial arena, changes in import costs can influence list price negotiations, reimbursement discussions, and contracting terms with large health systems that emphasize cost predictability. Pharmaceutical companies often respond by optimizing distribution patterns, negotiating broader supplier agreements, and exploring formulation changes that reduce reliance on imported excipients or single-use systems. For clinical research, tighter cross-border supply constraints may slow initiation of global trials or require contingency stocks for investigational products, prompting greater use of regional hubs and enhanced inventory planning. Importantly, the combined effect of tariff changes encourages an industry-wide focus on supply chain visibility, diversified supplier ecosystems, and contractual protections that together preserve patient access and trial integrity.

A detailed segmentation perspective that interweaves product classes, tumor indications, care settings, distribution pathways, administration routes, and corporate strategies to illuminate differentiated opportunities

A nuanced examination of segmentation clarifies how clinical utility and commercial strategy vary across product type, indication, end users, distribution channels, route of administration, and corporate ownership. Within product type, distinctions between PD-1 inhibitors and PD-L1 inhibitors remain clinically and commercially salient; the PD-1 class, represented by agents such as cemiplimab, nivolumab, and pembrolizumab, often leads in monotherapy durability across multiple tumor types, whereas PD-L1 inhibitors including atezolizumab, avelumab, and durvalumab are strategically positioned in specific indications and combinatorial niches. These modality-level differences inform trial design, safety management, and target product profiles.

Indication stratification further refines opportunity sets: tumor types such as bladder cancer, head and neck cancer, lung cancer, melanoma, and renal cell carcinoma each present distinct response patterns, lines of therapy considerations, and biomarker dependencies that influence label strategy and adoption timing. From the end user perspective, hospitals, research institutes, and specialty clinics drive demand through differing procurement cycles, clinical expertise, and formulary governance, which in turn affects outreach, clinical education, and service model investments. Distribution channel analysis shows that hospital pharmacies, online pharmacies, and retail pharmacies each contribute to patient access pathways, with hospital-based administration remaining central for many intravenous regimens while alternative channels support transitions to outpatient care.

Route of administration divides opportunities between intravenous and subcutaneous approaches, with subcutaneous formulations increasingly attractive for lowering infusion center burden and improving patient convenience, subject to clinical equivalence and reimbursement alignment. Company-level segmentation highlights strategic positioning by major developers-AstraZeneca, Bristol-Myers Squibb, Merck & Co., and Roche-each leveraging distinct pipelines, combination agendas, and geographic footprints to defend and expand clinical indications. Integrating these segmentation lenses provides a granular view of where competitive pressure, clinical unmet need, and operational complexity intersect, guiding commercialization, clinical trial prioritization, and partnership decisions.

How divergent regulatory landscapes, payer expectations, and care delivery ecosystems across major regions drive differentiated access strategies and evidence priorities for oncology biologics

Regional dynamics shape access, clinical adoption, and strategic priorities across the Americas, Europe, the Middle East and Africa, and Asia-Pacific, with each geography presenting distinct regulatory frameworks, reimbursement cultures, and care delivery models. In the Americas, advanced clinical trial infrastructure and centralized reimbursement mechanisms in certain markets drive early adoption and rapid integration of new indications, while stakeholder negotiations focus on outcomes and cost-effectiveness metrics. Europe, the Middle East and Africa feature a mosaic of national regulatory bodies and payer systems that value health technology assessment and budget impact analyses, requiring manufacturers to craft localized evidence packages and patient access programs.

Asia-Pacific markets vary widely in capacity and policy stance, from highly developed systems with fast regulatory review pathways to emerging markets where access depends on tiered pricing, local manufacturing partnerships, and government procurement strategies. Cross-region collaboration on clinical development often accelerates indication expansion, but companies must navigate import controls, regional manufacturing requirements, and divergent standards for biomarker testing. Collectively, these regional factors influence launch sequencing, evidence generation priorities, and the design of commercial models that balance global platform capabilities with local execution needs.

Competitive company-level analysis focused on portfolio optimization, combination strategies, formulation innovation, and operational capabilities that underpin long-term leadership in immune-oncology

Leading companies in the PD-1 and PD-L1 domain are refining portfolios to sustain long-term leadership by combining clinical differentiation with operational scale. AstraZeneca has focused on strategic combinations and oncology partnerships to bolster indications and complementary assets, leveraging its development networks to test novel pairings. Bristol-Myers Squibb maintains a broad immuno-oncology footprint and emphasizes lifecycle management via combination trials and supportive real-world evidence generation to sustain clinical relevance across lines of therapy. Merck & Co. continues to prioritize robust biomarker strategies and global clinical operations to preserve first-mover advantages in several tumor types, while Roche leverages diagnostic capabilities and deep oncology expertise to align companion testing with therapeutic deployment.

Across the competitive set, companies are advancing strategies such as developing subcutaneous formulations to reduce infusion burden, pursuing label expansions through combination regimens, and securing supply chain resilience via diversified manufacturing. Partnerships with biotech innovators and investments in digital health to support patient management and adherence are increasingly important differentiators. Intellectual property fences, regulatory commitments, and post-approval evidence plans all shape how these firms defend market positions and create new value in an environment where clinical nuance and operational excellence determine whether a therapy becomes a long-term standard component of oncologic care.

Actionable strategic and operational priorities for manufacturers and stakeholders to enhance access, drive clinical differentiation, and fortify supply and commercial resilience in oncology biologics

Industry leaders should align commercial, clinical, and operational levers to maximize patient access and sustain competitive advantage in the evolving checkpoint inhibitor landscape. Strategically, prioritize development pathways that generate biomarker-driven evidence and demonstrate additive benefit in combination regimens to capture clinically meaningful niches. Concurrently, accelerate investments in formulation innovation, particularly subcutaneous and fixed-dose options, to reduce administration complexity and expand outpatient treatment models, while ensuring comparative safety and pharmacokinetic equivalence.

Operationally, enhance supply chain resilience by diversifying suppliers, securing regional manufacturing capacity where feasible, and embedding scenario planning for trade policy shifts that may affect component availability. On the commercial front, engage early with payers and health technology assessment bodies to co-develop value frameworks and consider indication-specific contracting models that align price with demonstrated outcomes. Clinically, expand real-world evidence programs and registries to support long-term effectiveness and safety narratives, and leverage digital tools to improve patient identification, adherence, and survivorship care. Finally, pursue targeted partnerships and licensing arrangements with smaller innovators to access complementary modalities while managing capital allocations and regulatory risk.

A transparent multi-method research approach combining peer-reviewed literature, regulatory documents, expert interviews, and data triangulation to ensure clinical and commercial validity

The research underpinning this executive synthesis integrates a multi-method approach designed to triangulate high-quality evidence and expert insight. Secondary literature and peer-reviewed clinical studies provided the scientific foundation for mechanism-of-action interpretation, safety profiles, and comparative clinical outcomes, while regulatory filings and published prescribing information offered validated detail on approved indications and dosing strategies. Primary research included structured interviews with clinical investigators, hospital pharmacists, payers, and industry executives to capture forward-looking perspectives on adoption barriers, reimbursement dynamics, and operational constraints.

Data triangulation ensured alignment among disparate information streams, with a rigorous validation process that cross-checked clinical claims against trial registries and regulatory documents. The methodology emphasized transparency in assumptions and source citation, and the synthesis underwent peer review by therapeutic-area experts to ensure clinical accuracy and relevance. Where possible, real-world evidence and registry data were used to corroborate trial observations, and sensitivity checks addressed potential bias from selective reporting. This layered methodology balances depth of clinical insight with practical commercial intelligence to support informed decision-making.

Synthesis of clinical, commercial, and operational imperatives that will determine how checkpoint inhibitors translate scientific progress into durable, accessible cancer care

The current trajectory of PD-1 and PD-L1 inhibitors demonstrates a field in strategic transition: scientific advances and regulatory flexibility are expanding therapeutic potential, while commercial and operational pressures are reshaping how therapies reach patients. Success in this environment requires a dual focus on clinical differentiation-through biomarker-led development and rational combinations-and on pragmatic execution around manufacturing, distribution, and payer engagement. Stakeholders that balance innovation with operational rigor will be best positioned to deliver sustained patient benefit while navigating economic and policy headwinds.

Looking ahead, continued investment in translational science, adaptive trial designs, and real-world evidence generation will be critical to unlock new indications and optimize patient selection. At the same time, companies must proactively manage supply chain and pricing risks, engage with regional stakeholders to tailor access strategies, and pursue partnerships that accelerate complementary capabilities. In sum, the future of checkpoint inhibition will be determined not only by clinical breakthroughs but by the industry's ability to translate those breakthroughs into accessible, cost-effective care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging bispecific antibodies targeting PD-1 and additional immune checkpoints to overcome resistance mechanisms
  • 5.2. Increasing adoption of PD-1/PD-L1 inhibitors in earlier cancer treatment lines and adjuvant therapy settings to improve patient survival outcomes
  • 5.3. Advancements in predictive biomarkers and companion diagnostics to optimize patient selection for PD-1/PD-L1 therapies
  • 5.4. Combination regimens involving PD-1/PD-L1 inhibitors with novel targeted therapies and chemotherapy in solid tumors to enhance efficacy
  • 5.5. Development of next generation PD-1/PD-L1 inhibitors featuring improved safety profiles and reduced immune-related adverse events in clinical trials
  • 5.6. Expanding therapeutic indications for PD-1/PD-L1 inhibitors in rare cancers and non-oncology autoimmune conditions to broaden patient access
  • 5.7. Integration of real-world evidence and health economic analyses to support reimbursement decisions for PD-1/PD-L1 inhibitors across global markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. PD-1 & PD-L1 Inhibitors Market, by Product Type

  • 8.1. PD-1 Inhibitor
    • 8.1.1. Cemiplimab
    • 8.1.2. Nivolumab
    • 8.1.3. Pembrolizumab
  • 8.2. PD-L1 Inhibitor
    • 8.2.1. Atezolizumab
    • 8.2.2. Avelumab
    • 8.2.3. Durvalumab

9. PD-1 & PD-L1 Inhibitors Market, by Indication

  • 9.1. Bladder Cancer
  • 9.2. Head And Neck Cancer
  • 9.3. Lung Cancer
  • 9.4. Melanoma
  • 9.5. Renal Cell Carcinoma

10. PD-1 & PD-L1 Inhibitors Market, by End User

  • 10.1. Hospitals
  • 10.2. Research Institutes
  • 10.3. Specialty Clinics

11. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. PD-1 & PD-L1 Inhibitors Market, by Route Of Administration

  • 12.1. Intravenous
  • 12.2. Subcutaneous

13. PD-1 & PD-L1 Inhibitors Market, by Company

  • 13.1. AstraZeneca
  • 13.2. Bristol-Myers Squibb
  • 13.3. Merck & Co.
  • 13.4. Roche

14. PD-1 & PD-L1 Inhibitors Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. PD-1 & PD-L1 Inhibitors Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. PD-1 & PD-L1 Inhibitors Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Merck & Co., Inc.
    • 17.3.2. Bristol-Myers Squibb Company
    • 17.3.3. F. Hoffmann-La Roche Ltd
    • 17.3.4. AstraZeneca PLC
    • 17.3.5. Merck KGaA
    • 17.3.6. Pfizer Inc.
    • 17.3.7. BeiGene, Ltd.
    • 17.3.8. Innovent Biologics, Inc.
    • 17.3.9. CStone Pharmaceuticals
    • 17.3.10. Shanghai Junshi Biosciences Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PD-1 & PD-L1 INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLI